Press releases
- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGDN:DUS) traded at 78.00, -6.59% below its 52-week high of 83.50, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 78.00 |
---|---|
High | 78.00 |
Low | 78.00 |
Bid | 78.00 |
Offer | 79.00 |
Previous close | 78.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 17.96m |
Free float | 17.55m |
P/E (TTM) | 16.43 |
Market cap | 1.54bn USD |
EPS (TTM) | 5.23 USD |
Data delayed at least 15 minutes, as of May 29 2024 08:30 BST.
More ▼